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Abstract
Background: Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the
United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to
estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000–2007 in the U.S. and Canada.
Methods: Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD),
aged $20 years and on ART. Mortality rates were calculated using participants’ person-time from January 1, 2000 or ART
initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as
the average number of additional years that a person of a specific age will live, provided the current age-specific mortality
rates remain constant, was estimated using abridged life tables.
Results: The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years
and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000–2002 to
2006–2007. Men and women had comparable life expectancies in all periods except the last (2006–2007). Life expectancy
was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts ,350
cells/mm3.
Conclusions: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life
expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4
count remain.
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Introduction
Since the introduction of combination antiretroviral therapy
(ART), there have been considerable improvements in survival
among HIV-positive individuals, as regimens have become more
effective, simpler, and better tolerated [1–3]. The health gains
associated with ART use have been substantial at both the
individual and societal level [1,2]. ART is effective in increasing
the life span of HIV-positive individuals [2] and is associated with
a reduction in new infections [4–6]. However, in tandem with
increases in life expectancy following the introduction of ART,
HIV-positive individuals are increasingly experiencing age-related
co-morbid conditions, which are impacting both the length and
quality of their lives [7,8]. Studies show a small but persistent gap
in the life span between HIV-positive and -negative individuals,
particularly within key affected populations [2,9–11].
In the general populations of Canada and the United States
(U.S.), 2009 estimates of life expectancy at age 20 years were 59.7
and 57.0 years for men and 63.9 and 61.7 years for women,
respectively [12]. While ART has led to significant increases in
survival among HIV-positive adults globally, the effect of ART on
life expectancy in the U.S. and Canada has not been well
characterized. No study has had a sufficient sample size to
determine whether gains in life expectancy for HIV-positive
individuals are similar to those observed in the general population,
or are similar across sex, race, or transmission groups. The
objective of this study is to examine temporal changes in life
expectancy from 2000 to 2007 among HIV-positive individuals on
ART in the U.S. and Canada and to compare life expectancy by
selected sociodemographic and clinical characteristics.
Methods
Study Population
Estimates of life expectancy were obtained from mortality rates
from the North American AIDS Cohort Collaboration on
Research and Design (NA-ACCORD), a multi-site collaboration
of interval and clinical cohorts of HIV-positive individuals in
Canada and the U.S. NA-ACCORD is the North American
regional collaboration sponsored by the National Institute of
Health’s International Epidemiological Databases to Evaluate
AIDS (IeDEA) consortium. Details on the NA-ACCORD
collaboration and participating cohort studies have been published
previously [13]. Briefly, each contributing cohort has developed
standardized cohort-specific methods of data collection. At
scheduled intervals, these cohorts submit data regarding partici-
pants’ demographic characteristics, ART prescription informa-
tion, dates and results of laboratory tests including HIV-1 RNA
(viral load) and CD4 count, clinical diagnoses, and vital status.
These data are transferred securely to the NA-ACCORD central
Data Management Core, where they undergo quality control for
completeness and accuracy before they are combined into
harmonized data files. Quality control includes instituting
measures to reduce the probability that an individual was
participating in more than one cohort.
HIV-positive individuals in NA-ACCORD were included in
this analysis if they were aged 20 years or older (due to small
numbers at younger ages) at the start of each period, had no prior
antiretroviral therapy experience when observed to initiate ART,
and had a CD4 cell count measurement at or within six months
following ART initiation (participating NA-ACCORD sites are
described in Appendix S1). ART was defined as a multi-class
regimen containing at least three antiretroviral drugs, including a
protease inhibitor, a non-nucleoside reverse-transcriptase inhibi-
tor, or three nucleoside reverse-transcriptase inhibitors. The study
period was restricted to 1 January 2000 and 31 December 2007, a
time period often characterized as the modern ART era [14], in
order to produce estimates that are more relevant to the current
context of HIV antiretroviral management. All study participants
were included either when they were first dispensed ART, or from
the start of the study period if initiation was pre-2000, regardless of
whether they later discontinued or modified their therapeutic
regimen. The human subjects activities of the NA-ACCORD has
been approved by the Johns Hopkins School of Medicine
institutional review board (NA_00002683) as well as the local
institutional review boards at each of the participating cohorts.
Additional information on ethical approval and consent proce-
dures for each individual cohort is described in Appendix S1.
Primary Outcome: Life Expectancy
Life expectancy is defined as the average number of additional
years that a person of a specific age will live, if the current age-
specific mortality rates remain constant over the course of the
individual’s lifetime [15]. We interpret life expectancy as a
summary measure of age-specific mortality patterns in our defined
population [16,17]. Although single year-of-age life tables are used
to calculate life expectancy for large populations such as the entire
U.S. population with complete death capture via a vital statistics
registry [18], we used abridged life tables (with data aggregated
into age intervals) due to the relatively small size of our study
population and number of deaths therein [15]. Each participating
cohort has procedures in place for the ascertainment of deaths for
their participants, although these methods are not uniform across
all cohorts. Information about deaths among NA-ACCORD
participants was obtained from each participating cohort, either
through linkages with vital statistics registries, physician report
obtained in medical record, or through active follow-up. A
sensitivity analysis estimated mortality rates restricting to cohorts
that obtained information on deaths from linkage to vital statistics
registries.
Statistical Analyses
Mortality rates are the building blocks of life expectancy
estimates. We calculated all-cause mortality rates (per 1,000
person-years) by dividing the total number of deaths by the total
number of person-years of observation. Person-years for estimat-
ing mortality rates were accumulated from ART initiation (or
January 1, 2000 for those who initiated prior to this date) until
death date, loss to follow-up (defined as 6 months after the
participant’s last CD4 cell count or viral load measurement), or
December 31, 2007, whichever came first. Each participant’s
person-years contribution was partitioned into three calendar eras
(1/1/2000–12/31/2002, 1/1/2003–12/31/2005, and 1/1/2006–
12/31/2007) and four age groups (20–34, 35–44, 45–54, $55
years), categorizations designed to ensure that cells had sufficient
number of deaths to calculate rates of death. We further stratified
the calendar- and age-specific mortality rates by sex (male vs.
female), race (non-white vs. white), HIV transmission risk (men
who have sex with men (MSM), injection drug use (IDU) including
MSM who inject drugs, and other transmission groups), and
baseline CD4 cell count measured at, or within 6 months of, ART
initiation (,350 cells/mm3 vs. $350 cells/mm3) to examine
differences in life expectancy by these characteristics.
Mortality rates are susceptible to bias from informative
censoring. To address this potential source of bias, we used
weighted regression methods to estimate mortality rates [19] and
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compared the life expectancy estimated using unweighted and
weighted regression methods for mortality rates, which are
described in more detail in Appendix S2. Abridged life tables
constructed as part of this study were based on widely used and
standardized methods employed by Chiang [15] and outlined in
greater detail in an earlier study [2]. Estimates of life expectancy,
stratified by several indicators described above, were taken at age
20 years for individuals on ART in the NA-ACCORD. These
estimates were calculated under the assumption that any deaths
(and therefore person-years contributed from the decedents) occur
uniformly in any defined calendar period [15].
Results
Our study population consisted of 22,937 treatment-naive ART
initiators age $20 years. Participants contributed 82,022 person-
years and 1,622 deaths for an overall unweighted (i.e., without
accounting for censoring weights) mortality rate of 19.8 [95%
Confidence Interval (CI): 18.8, 20.8] per 1,000 person-years. In a
sensitivity analysis restricted to only those who were observed to
initiate ART during our study period (18,591 participants
contributing 1,057 deaths), the overall unweighted mortality rate
was 18.9 (95% CI: 17.8, 20.1) per 1,000 person-years.
Table 1 describes the demographic characteristics of included
participants, overall and by calendar period. As individuals can
contribute person-time to a number of periods, these calendar
periods are not mutually exclusive. Of the entire sample, 77%
were male, 20% had a history of IDU, 62% were non-white, and
72% initiated ART with a CD4 cell count,350 cells/mm3. Other
than age, demographic and clinical characteristics remained stable
across periods.
Table 2 characterizes the study sample in terms of number of
deaths and unweighted mortality rates (per 1,000 person-years). In
general, mortality rates were highest among individuals with IDU
history (34.5, 95% CI: 31.9, 37.4) compared with MSM and other
transmission groups, non-whites (22.4, 95% CI: 21.1, 23.8)
compared with whites, and individuals with CD4 counts ,350
cells/mm3 (23.3, 95% CI: 22.1, 24.6) compared with those with
CD4 $350 cells/mm3.
Figure 1 shows unweighted age-specific mortality rates for the
three periods under observation. As expected, age-specific
mortality rates were highest in the earliest period and lowest in
the most recent period. In a sensitivity analysis, we estimated
mortality rates in fourteen participating cohorts that collect
information about deaths by linking to death registries to four
that do not; although we see a slightly higher mortality rate among
cohorts with death registry matches, the impact on life expectancy
estimates appears minimal (data not shown) (see Appendix S3 for
more information).
Table 3 presents overall life expectancy estimates based on
unweighted mortality rates and mortality rates weighted for loss to
follow-up. The unweighted and weighted life expectancy estimates
were similar, with overall life expectancy estimates of 42.6 and
42.7 years, respectively; however the standard error was slightly
larger when the unweighted mortality rates were used (SE 0.2 vs.
SE 0.1). Over the entire study period, women had similar life
expectancies to men, IDUs had lower life expectancies than MSM
and individuals with other risk factors, non-whites had lower life
expectancies than whites, and those with CD4 count ,350 cells/
mm3 had a lower life expectancy than those with CD4 count
$350 cells/mm3. Finally, in a sensitivity analysis (further described
in Appendix S4), when the sample was restricted to those who
initiated therapy after 2000, life expectancy at 20 years increased
to 45.1 years (SE 0.3).
Table 4 and Figure 2 show life expectancy at age 20 years by
calendar period and by sociodemographic characteristics based on
Table 1. Demographic and clinical characteristics of participants, overall and for those contributing to each calendar period
(n = 22,937).
Period 1 (2000–2002)
n (%)
Period 2 (2003–2005)
n (%)
Period 3 (2006–2007)
n (%)
Overall (2000–2007)
n (%)
Age at start of ART
20–34 2,774(25) 3,331(21) 3,036(17) 5,808(25)
35–44 4,938 (45) 6,670 (42) 6,679 (38) 9,622 (42)
45–54 2,486 (23) 4,248 (27) 5,737 (32) 5,692 (25)
55+ 743 (7) 1,464 (9) 2,307 (13) 1,823 (8)
Sex
Female 2,509 (23) 3,733 (24) 4,206 (24) 5,352 (23)
Male 8,432 (77) 11,980 (76) 13,553 (76) 17,585 (77)
Mode of transmission
Injection drug use 2,470 (23) 3,219 (20) 3,513 (20) 4,684 (20)
MSM 4,324 (40) 5,990 (38) 6,911 (39) 8,842 (39)
Other 4,147 (38) 6,504 (41) 7,335 (41) 9,411 (41)
Race
White 4,410 (40) 6,214 (40) 6,808 (38) 8,643 (38)
Non-white 6,531 (60) 9,499 (60) 10,953 (62) 14,294 (62)
CD4 cell count at start of ART (cells/mm3)
,350 7,578 (69) 11,402 (73) 12,884 (73) 16,615 (72)
$350 3,363 (31) 4,311 (27) 4,875 (28) 6,322 (28)
Note: MSM, men who have sex with men; ART, combination antiretroviral therapy.
doi:10.1371/journal.pone.0081355.t001
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unweighted mortality rates. Life expectancy at age 20 years
increased with calendar time, from 36.1 (SE 0.5) years in 2000–
2002 to 51.4 (SE 0.5) years in 2006–2007. There was an increase
in life expectancy among all groups over calendar time with the
exception of individuals with a history of IDU, who had the lowest
recorded life expectancies in all periods.
Table 2. Population size, deaths, and unweighted mortality rate, overall and by select categories, 2000 to 2007.
Population Deaths Person Years
Unweighted
mortality rate* (95% CI**)
Overall 22,937 1,622 82,022 19.8 (18.8, 20.8)
Sex
Female 5,352 366 19,171 19.1 (17.2, 21.2)
Male 17,585 1,256 62,851 20.0 (18.9, 21.1)
Mode of transmission
Injection drug use 4,684 598 17,326 34.5 (31.9, 37.4)
Men who have sex with men 8,842 403 32,139 12.5 (11.4, 13.8)
Other transmission groups 9,411 621 32,508 19.1 (17.7, 20.7)
Race
White 14,294 539 33,717 16.0 (14.7, 17.4)
Non-white 8,643 1,083 48,305 22.4 (21.1, 23.8)
CD4 cell count at start of ART (cells/mm3)
,350 16,615 1,351 58,003 23.3 (22.1, 24.6)
$350 6,322 271 24,019 11.3 (10.0, 12.7)
*Per 1,000 person-years.
**CI: Confidence Interval.
Note: ART, combination antiretroviral therapy.
doi:10.1371/journal.pone.0081355.t002
Figure 1. Age-specific unweighted mortality rates (per 1000 person-years), by calendar-period, among individuals on ART in the
NA-ACCORD, 2000–2007. Note: PY, person-years; ART, combination antiretroviral therapy.
doi:10.1371/journal.pone.0081355.g001
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Discussion
Based on current patterns of ART use among participants
observed from 2000 to 2007 in the NA-ACCORD, a 20-year-old
individual on ART today in the U.S. or Canada would expect to
live into their early 70 s, a life expectancy that approaches that of a
20-year-old person in the general population [12]. Life expectancy
estimates for the general population at age 20 years in 2009 were
59.7 and 57.0 years for men and 63.9 and 61.7 years for women,
in Canada and the U.S., respectively [12]. Indeed, given that
many individuals living with HIV have demographic, clinical, and
behavioral characteristics associated with greater morbidity and
mortality than the general population [20,21], the gap in life
expectancy may be attributable to other lifestyle factors and not
just HIV infection.
Importantly, our results are not confounded by previous
antiretroviral use, as all participants were treatment-naive before
initiating combination therapy. Weighted and unweighted rates
overall and by calendar period produced similar results suggesting
that our adjusted estimates are robust to any potential for
informative censoring bias from the variables that were included in
our model. Life expectancy does differ markedly by transmission
group, race, and CD4 cell count at ART initiation; in particular, it
is notably lower in individuals with a history of IDU, who are non-
white, and who began ART with lower CD4 cell counts.
In the early years of ART availability, mortality was highest in
the first year after ART initiation, but this has decreased over
time. The modern ART era, in which mortality has become
increasingly dependent on duration of ART, is characterized by a
greater proportion of patients with longer follow-up. Therefore,
the increase in life expectancy in the more recent time periods may
reflect both a lower mortality rate in patients initiating ART and
the mortality in those with a longer duration of ART use.
Our results are consistent with previous studies that have
examined the life expectancy of HIV-positive individuals on ART
[22]. While prior studies have observed similar decreases in
mortality and increases in life expectancy among HIV-positive
individuals as a result of ART [23], such findings have often been
localized at the provincial or state level, and may now be less
relevant to the current context of antiretroviral care [24,25].
Furthermore, this is the first study to examine life expectancy in
such a large sample of heterogeneous HIV-positive individuals on
ART across the U.S. and Canada, and therefore provides novel
data from this region.
Table 3. Life expectancy estimates (LEE) and standard errors
(SE) at age 20 years using weighted and unweighted mortality
rates, 2000 to 2007.
Unweighted
(LEE, SE)
Weighted*
(LEE, SE)
Overall 42.6 (0.2) 42.7 (0.1)
Sex
Female 43.7 (0.5) 43.9 (0.3)
Male 42.4 (0.3) 42.4 (0.2)
Mode of transmission
Injection drug use 29.0 (0.5) 29.1 (0.2)
Men who have sex with men 56.9 (0.5) 57.3 (0.3)
Other transmission groups 49.7 (0.5) 50.1 (0.3)
Race
White 52.0 (0.4) 52.1 (0.2)
Non-white 38.0 (0.3) 38.0 (0.1)
CD4 cell count at start of ART (cells/mm3)
,350 38.7 (0.3) 38.8 (0.14)
$350 54.4 (0.5) 54.6 (0.27)
Note: LEE, life expectancy estimate (years); SE, standard error; ART, combination
antiretroviral therapy.
*In effort to reduce bias from informative censoring, we used weighted
regression methods to estimate mortality rates, using an indicator variable that
was created to identify participants who were lost to follow-up. Further details
are available in Appendix S2.
doi:10.1371/journal.pone.0081355.t003
Table 4. Life expectancy estimates (LEE) and standard errors (SE) at age 20 years using unweighted mortality rates, by calendar
period, 2000 to 2007.
2000–2002 (LEE, SE) 2003–2005 (LEE, SE) 2006–2007 (LEE, SE)
Overall 36.1 (0.5) 45.2 (0.4) 51.4 (0.5)
Sex
Men 35.9 (0.5) 44.3 (0.5) 53.4 (0.6)
Women 36.6 (1.0) 48.4 (0.8) 47.3 (0.5)
Mode of transmission
Injection drug use 29.5 (0.9) 31.0 (0.7) 28.8 (0.4)
Men who have sex with men 53.3 (0.9) 57.4 (0.8) 69.3 (1.0)
Other transmission groups 43.5 (0.9) 52.4 (0.7) 56.1 (0.9)
Race
White 52.7 (0.8) 53.6 (0.7) 56.9 (0.9)
Non-white 29.7 (0.6) 40.7 (0.5) 48.4 (0.6)
CD4 cell count at start of ART (cells/mm3)
,350 31.4 (0.6) 40.8 (0.5) 46.9 (0.6)
$350 48.8 (0.9) 58.4 (0.8) 68.6 (1.2)
Note: LEE, life expectancy estimate (years); SE, standard error; ART, combination antiretroviral therapy.
doi:10.1371/journal.pone.0081355.t004
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Figure 2. Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic
characteristics, 2000–2007. Panel A: Life expectancy at age 20 years, overall. Panel B: Life expectancy at age 20 years, by sex. Panel C: Life
expectancy at age 20 years, by transmission group. Panel D: Life expectancy at age 20 years, by race. Panel E: Life expectancy at age 20 years, by CD4
cell count (cells/mm3) at ART initiation.
doi:10.1371/journal.pone.0081355.g002
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The absence of significant differences in life expectancy by sex,
and the higher life expectancy of men in the latest period suggests
that there is in fact a sex differential in life expectancy in our study.
In general, in high-income countries such as the U.S. and Canada
we expect women to have higher life expectancies than men,
which was not evident in our findings [12]. Similar life
expectancies by sex or higher life expectancy for men suggest
that women may be accessing HIV-related care at later stages of
HIV disease than men in Canada and the U.S., which has
significant public health ramifications. The sex differential, noted
here, may also be explained in part due to the fact that general
population comparisons better represent all men and women,
while HIV-positive men here are weighted towards MSM and
women toward IDU. Variation in levels of education and income,
as well as access to the health care system, social stigma, and
marginalization are other factors that may influence the observed
differences by sex [26].
There are also considerable differences in life expectancy by
HIV transmission group, with lower life expectancies reported in
all periods for individuals with a history of IDU. This finding is
consistent with previous findings from the ART Cohort Collab-
oration (a multisite cohort collaboration that includes seven sites in
North America) and work done in British Columbia, Canada
[2,27]. We hypothesize a number of possible reasons for these
differences, including increased comorbidity with greater non-
AIDS related mortality, as well as challenges with ART
adherence, active drug use, hepatitis C co-infection, housing
instability, and lower socioeconomic status. Our findings here
clearly illustrate that individuals with IDU history have not seen
the increases in life expectancy that are evident in other groups.
Differences in life expectancy by race were also evident, with
white individuals having higher life expectancies in all periods. As
with persons with a history of IDU, these differences in life
expectancy may be reflective of underlying differences in
socioeconomic conditions, access to care, and health insurance
coverage, suggesting an urgent need for strategies and programs to
combat these inequities [28,29]. However, we note that the gap in
life expectancy between white and non-white individuals has
decreased substantially, from 23.0 years in 2000–02 to 8.5 years in
2006–07.
Additional differences in life expectancies were noted by CD4
cell count at ART initiation in all periods. These findings may lend
additional support to the earlier initiation of ART, in accordance
with both the DHHS guidelines recommending universal therapy
[30] and the 2012 International AIDS Society-USA (IAS-USA)
guidelines, which recommend use of ART for all HIV-positive
individuals regardless of CD4 cell count, except in the case of long-
term non-progressors and elite controllers [3]. While our sample
size limited our ability to analyze differences in life expectancy by
more than two CD4 cell count strata, further analyses examining
life expectancies for individuals starting ART with CD4 counts
.500/mm3 would be beneficial.
In reviewing these findings, there are several potential
limitations that readers of our work should consider. A caveat of
life expectancy analyses in general is that they may underestimate
more recent improvements in extending life since age-specific
mortality rates are based on a given point in time and assumed to
apply for the duration of an individual’s life [22]. Also, our results
can only be generalized to those newly initiating ART, and not
those with previous exposure to antiretroviral therapy. Although
this collaboration includes the largest number of HIV-positive
individuals and broadest geographic distribution in the U.S and
Canada analyzed to-date, these individuals may not be fully
representative of the epidemic in the entire region. However,
previous analyses of the NA-ACCORD indicate that it does
represent the demography of the epidemic in the U.S. [31]. Next,
cohorts in this collaboration may under-represent those at greatest
risk of death, as such individuals are less likely to seek care or to
remain under care at one clinic. Thus, cohorts that did not link to
vital statistics may miss deaths that occurred outside of the clinic
setting. However, most participants (88%) were from cohorts that
did link to vital statistics data. To further investigate this issue, we
conducted sensitivity analyses taking into account loss to follow-up,
and were reassured to find little differences in our estimates.
Variations due to small numbers may also affect our estimates,
especially due to the truncation of age intervals at older ages and
the small number of deaths observed for some time intervals. We
addressed the impact of small numbers by smoothing rates and
examining the distribution of deaths over a calendar period.
Finally, due to the increased risk of age-related co-morbidities
among HIV-positive adults, it is possible life expectancy may
plateau or decrease in the future; it will be important to monitor
life expectancy estimates as more adults age with HIV.
In conclusion, the results of this study document increasing
longevity for individuals living with HIV in the U.S. and Canada.
The marked increase in life expectancy at age 20 from 36.1 years
in 2000–2002 to 51.4 years in 2006–2007 is a testament to the
improvements and overall success of ART. However, large
differences in life expectancy persist between certain sub-groups
of patients. Future work should consider specific reasons for these
life expectancy gains, overall and within each sub-group. These
data will be vital to target priorities for improvements in health
services. Finally, in addition to quantity, future work should
consider quality of life, as the proportion of individuals aging with
HIV continues to grow.
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